Onderneming Altimmune Inc Nasdaq
Aandelen
US02155H1014
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Treatments for Various Diseases and Disorders, and Vaccines
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | -726,47% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | -726,47% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 30-11-18 |
Director of Finance/CFO | 66 | 31-12-21 | |
Anthony Blandin
CMP | Compliance Officer | - | 01-02-22 |
M. Roberts
CTO | Chief Tech/Sci/R&D Officer | 65 | 01-12-12 |
Bertrand Georges
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-15 |
M. Harris
CTO | Chief Tech/Sci/R&D Officer | 71 | 09-09-19 |
Karen Smith
PRN | Corporate Officer/Principal | - | 01-09-20 |
Andrew Shutterly
AUD | Comptroller/Controller/Auditor | - | 01-10-20 |
56 | - | ||
Raymond Jordt
PRN | Corporate Officer/Principal | 52 | 01-01-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 01-04-10 |
Mack Gill
BRD | Director/Board Member | 72 | 01-08-04 |
Philip Hodges
BRD | Director/Board Member | 56 | 01-09-03 |
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 30-11-18 |
David Drutz
BRD | Director/Board Member | 86 | 01-01-10 |
Wayne Pisano
BRD | Director/Board Member | 69 | 30-08-18 |
Diane Jorkasky
BRD | Director/Board Member | 72 | 11-05-20 |
Catherine Sohn
BRD | Director/Board Member | 71 | 23-03-23 |
Klaus Schafer
BRD | Director/Board Member | 74 | 01-07-12 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 70 902 191 | 70 351 925 ( 99,22 %) | 0 | 99,22 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |